Fig. 3
From: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers
Association of TET1 status and clinical outcomes in the discovery cohort. a. Histogram depicting proportions of patients achieved objective response (ORR) in TET1-MUT and TET1-WT groups. (n = 515; 4 patients with best overall response not evaluable). b. Histogram depicting proportions of patients derived durable clinical benefit (DCB) in TET1-MUT and TET1-WT groups. (n = 495; 24 patients with durable clinical benefit not evaluable). c. Kaplan-Meier estimates of progression-free survival (PFS) in the discovery cohort comparing patients with TET1-MUT with their respective WT counterparts. (n = 519). d. Kaplan-Meier estimates of overall survival (OS) in the discovery cohort comparing patients with TET1-MUT with their respective WT counterparts. (n = 490; 29 patients with no OS information available)